| Trial Status | Recruiting |
| Dates | Date of activation: 08-Nov-11 |
| Data management at EORTC | Mailbox |
| Phase | 3 |
| Randomized trial | Yes |
| Type | Adjuvant |
| Targeted Sample size | EORTC Groups: 3806 - All Groups: 3806 |
| Number of steps | 1 |
| Drug | Fluorouracil Carboplatin Cyclophosphamide Docetaxel Doxorubicin Epirubicin Pertuzumab Paclitaxel Trastuzumab |
| Study Staff | Fatima Cardoso (Study Coordinator) - Champalimaud Cancer Center, Lisboa Jan Bogaerts (Statistician) - EORTC Headquarters, Brussels Carlo Messina (Coordinating Physician) - EORTC Headquarters, Brussels Melanie Beauvois (Project Manager) - EORTC Headquarters, Brussels, melanie.beauvois( at )eortc.be, +32 27741687 |
| Type of cancer | Breast |
| Participating Groups | Breast International Group(Coordinating Group) EORTC Breast Cancer Group |
| Centers authorized by EORTC | Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet (Brussels, Belgium) - Inst. 101 Universitair Ziekenhuis Antwerpen (Edegem, Belgium) - Inst. 117 Cliniques Universitaires De Mont Godinne (Yvoir, Belgium) - Inst. 123 U.Z. Leuven - Campus Gasthuisberg (Leuven, Belgium) - Inst. 147 AZ Groeninge Kortrijk - Campus Loofstraat (Kortrijk, Belgium) - Inst. 1257 Rambam Medical Center (Haifa, Israel) - Inst. 910 |
| Protocol summary | Cancer.gov (PDQ) ClinicalTrials.gov |
| NCT number | NCT01358877 |
| EudraCT | 2010-022902-41 |
| Protocol documents in PDF (requires password) | Study documentation |